Last reviewed · How we verify
Melphalan+Prednisolone
Melphalan is an alkylating agent that damages DNA, while prednisolone is a corticosteroid that suppresses immune function; together they work to kill cancer cells and reduce inflammation.
Melphalan is an alkylating agent that damages DNA, while prednisolone is a corticosteroid that suppresses immune function; together they work to kill cancer cells and reduce inflammation. Used for Multiple myeloma, Light chain deposition disease.
At a glance
| Generic name | Melphalan+Prednisolone |
|---|---|
| Sponsor | Cigdem Sahinbas YILMAZ |
| Drug class | Alkylating agent + Corticosteroid combination |
| Target | DNA (melphalan); glucocorticoid receptor (prednisolone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Melphalan is a nitrogen mustard derivative that cross-links DNA strands, preventing cell division and inducing apoptosis in rapidly dividing cells. Prednisolone enhances the cytotoxic effect and provides immunosuppression and anti-inflammatory benefits. This combination is commonly used in multiple myeloma treatment protocols.
Approved indications
- Multiple myeloma
- Light chain deposition disease
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Infection
- Nausea and vomiting
- Mucositis
- Secondary malignancy
- Hyperglycemia (prednisolone-related)
- Immunosuppression complications
Key clinical trials
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (PHASE2)
- Tazemetostat Plus CHOP in 1L T-cell Lymphoma (PHASE2)
- Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation (PHASE2)
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease (PHASE1)
- Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant (PHASE1, PHASE2)
- VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma
- Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melphalan+Prednisolone CI brief — competitive landscape report
- Melphalan+Prednisolone updates RSS · CI watch RSS
- Cigdem Sahinbas YILMAZ portfolio CI